High-throughput assay identifies novel OTULIN inhibitors in drug discovery using a bioluminescent sensor.
A luciferase-based reporter, N-Rluc-Ub-Ub-C-Rluc was developed to selectively monitor M1-deubiquitinase activity via catalytic signal amplification. This high-throughput assay identified Baicalein and Lumacaftor as novel OTULIN inhibitors from an FDA-approved compound...
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: